CorestemChemon's Neuronata-R Advances toward ALS Stem Cell Market in Korea and the U.S. CorestemChemon is making significant strides in ALS stem cell therapy with Neuronata-R, focusing on regulatory processes in Korea and expanding into the U.S. market.

CorestemChemon's Neuronata-R Advances toward ALS Stem Cell Market in Korea and the U.S. #South_Korea #Seoul #Neuronata-R #CorestemChemon #ALS_Therapies

Neuronata-R® Phase 3 Trial Delivers Positive Results, Pushing Towards FDA Approval Pathway CorestemChemon's Neuronata-R® shows potential in ALS treatment, highlighting significant improvements in specific patient subgroups at PACTALS 2025.

Neuronata-R® Phase 3 Trial Delivers Positive Results, Pushing Towards FDA Approval Pathway #South_Korea #Seoul #ALS #Neuronata-R #CorestemChemon

CorestemChemon Collaborates with ATG Lifetech to Enhance Preclinical Research Services CorestemChemon announces a partnership with ATG Lifetech, aiming to innovate preclinical solutions for drug discovery through advanced technologies.

CorestemChemon Collaborates with ATG Lifetech to Enhance Preclinical Research Services #South_Korea #Seoul #preclinical_CRO #CorestemChemon #ATG_Lifetech